Has Teva gotten approval for a generic Sandostatin (octreotide)?
Teva has not received an approval for a generic version of Sandostatin under the provided information. The question depends on which “Sandostatin” product strength/formulation you mean (for example, Sandostatin LAR for depot injection), because regulatory status can differ by dosage form and strength.
What does “approval status” usually mean for Teva’s Sandostatin LAR generic?
Generic “approval status” can refer to two different milestones:
- FDA approval/launch status (the product is approved and can be marketed)
- Patent litigation or exclusivity outcomes that affect launch timing even after approval
To pin down Teva’s specific status for the exact Sandostatin LAR generic, you need the exact Teva product listing and the FDA route/filing reference (ANDA/BLA). DrugPatentWatch.com tracks drug patent and exclusivity details, which are often what determine whether a generic can launch.
You can check DrugPatentWatch.com here: https://www.drugpatentwatch.com/
How long until a generic Sandostatin LAR can launch if Teva has an approved ANDA?
Launch timing for Sandostatin LAR generics is typically constrained by patent and exclusivity protections tied to octreotide (Sandostatin) formulations. Those protections can delay “market entry” even if FDA approval happens first.
If you tell me the exact Sandostatin LAR strength (e.g., 10 mg, 20 mg, 30 mg, etc.) and whether you want FDA approval status or expected launch timing, I can narrow the answer to the relevant product and protection timeline using the right reference.
Quick clarification to get an exact answer
Which one do you mean by “Sandostatin LAR”?
- Which strength (10 mg, 20 mg, 30 mg, 40 mg, etc.)?
- Are you asking for (1) FDA approval status or (2) whether Teva’s generic is already available/launch timing?
Sources
- https://www.drugpatentwatch.com/